Best Niche Antibody-based Biologics

BCMA (CY/Fc-Fusion)

BCMA (CY/Fc-Fusion)

Part No. C7011F
Regular price
$ 499.00
Sale price
$ 499.00
Regular price
Out of Stock
Unit price

BCMA is an integral membrane type I protein that is preferentially expressed in mature B lymphocytes , but not in T-cells or monocytes.

Interacting protein(s): BAFF, APRIL
Related products: TNF-Receptor Superfamily

Read all details below including Quick Specs.

** Please note: For orders over 1 mg, please inquire here

Quick Specs

Species: Macaque
Catalog no.: C7011F
Synonym: TNFRSF17, BCM, BCMA, CD269
Tag: mouse IgG2a-Fc
GenBank accession: EHH60172.1
SwissPro accession: G7Q0I4
Construction: macaque BCMA (A5–K49)-m.IgG-Fc
Expression host: 293T
MW (calculated): 32,247 daltons
MW (SDS-PAGE): 34 Kd
Abs 0.1% (= 1 mg/ml): 1.121
Purity: 95 %


BCMA is an integral membrane type I protein that is preferentially expressed in mature B lymphocytes , but not in T-cells or monocytes. BCMA binds to the tumor necrosis factor (ligand) superfamily, BAFF and APRIL and its cytoplasmic tail associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3, TRAF5, TRAF6 and activates NF-κB, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. It was shown that APRIL stimulates in vitro proliferation of primary B and T cells and increases spleen weight due to accumulation of B cells in vivo. APRIL binds to BCMA and TACI (transmembrane activator and CAML-interactor) and competes with BAFF for receptor binding. Soluble BCMA and TACI specifically prevent binding of APRIL and block APRIL-stimulated proliferation of primary B cells. BCMA-Fc also inhibits production of antibodies against keyhole limpet hemocyanin and Pneumovax in mice, indicating that APRIL and/or BAFF signaling via BCMA and/or TACI are required for generation of humoral immunity. Thus, APRIL-BAFF and BCMA-TACI form two ligands-two receptors pathway involved in stimulation of B and T cell function.

Amino Acid Sequence.


1. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. Laabi Y., Gras M.P., Carbonnel F., Brouet J.C., Berger R., Larsen C.-J., Tsapis A. EMBO J. 11:3897-3904 (1992)

2. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Yu G., Boone T., Delaney J., Hawkins N., Kelley M.J., Ramakrishnan M., McCabe S., Qiu W.R., Kornuc M., Xia X.-Z., Guo J., Stolina M., Boyle W.J., Sarosi I., Hsu H., Senaldi G., Theill L.E. Nat. Immunol. 1:252-256 (2000)

3. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. Pelletier M, Thompson JS, Qian F, Bixler SA, Gong D, Cachero T, Gilbride K, Day E, Zafari M, Benjamin C, Gorelik L, Whitty A, Kalled SL, Ambrose C, Hsu YM. J Biol Chem.278(35):33127-33 (2003)

4. Ligand-receptor binding revealed by the TNF family member TALL-1. Liu Y., Hong X., Kappler J., Jiang L., Zhang R., Xu L., Pan C.-H., Martin W.E., Murphy R.C., Shu H.-B., Dai S., Zhang G. Nature 423:49-56 (2003)